File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Phase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population

TitlePhase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population
Authors
KeywordsAdvanced hepatocellular carcinoma
Asian
Lung metastasis
Sorafenib
Issue Date2009
PublisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www3.interscience.wiley.com/cgi-bin/jhome/28741
Citation
Cancer, 2009, v. 115 n. 2, p. 428-436 How to Cite?
AbstractBackground: The current study was a phase 2 open-label study to evaluate the efficacy and tolerability of single-agent sorafenib in the treatment of advanced HCC patients in a hepatitis B-endemic Asian population. METHODS: Patients with advanced hepatocellular carcinoma (HCC) received sorafenib at a dose of 400 mg twice daily in 4-week cycles. Tumor response was assessed every 3 cycles using Response Evaluation Criteria in Solid Tumors criteria. RESULTS: Fifty-one patients were enrolled in the study and were treated with sorafenib for at least 12 weeks. The median age was 56 years (range, 28-79 years). Approximately 90% had hepatitis B virus-related HCC. Thirty-six (71%) patients had underlying Child-Pugh A cirrhosis, 13 (26%) Child-Pugh B, and 2 (3%) Child-Pugh C. Four (8%) patients achieved partial responses, and 9 (18%) patients had stable disease for at least 12 weeks. The median overall survival was 5 months (range, 4-17 months). Patients without extrahepatic spread, particularly without lung metastasis (P<.01), are more likely to benefit from sorafenib treatment. The most common toxicities were diarrhea (67%), malaise (55%), and hand-foot-skin reaction (54%). The majority of patients had transient liver function derangement. Patients with and without underlying portal vein thrombosis had similar therapeutic benefits and likewise shared a similar treatment-related toxicity profile with sorafenib treatment. CONCLUSIONS: Single-agent sorafenib demonstrates good efficacy and acceptable tolerability in treating an advanced HCC patient population in a hepatitis B-endemic area. The presence of lung metastasis predicts poor response to sorafenib in advanced HCC patients. © 2009 American Cancer Society.
Persistent Identifierhttp://hdl.handle.net/10722/132648
ISSN
2015 Impact Factor: 5.649
2015 SCImago Journal Rankings: 3.188
ISI Accession Number ID
Funding AgencyGrant Number
University of Hong Kong
Funding Information:

Supported in part by the University of Hong Kong hapatocellular carcinoma research fund.

References

 

DC FieldValueLanguage
dc.contributor.authorYau, Ten_HK
dc.contributor.authorChan, Pen_HK
dc.contributor.authorNg, KKen_HK
dc.contributor.authorChok, KSHen_HK
dc.contributor.authorCheung, TTen_HK
dc.contributor.authorFan, STen_HK
dc.contributor.authorPoon, RTen_HK
dc.date.accessioned2011-03-28T09:27:23Z-
dc.date.available2011-03-28T09:27:23Z-
dc.date.issued2009en_HK
dc.identifier.citationCancer, 2009, v. 115 n. 2, p. 428-436en_HK
dc.identifier.issn0008-543Xen_HK
dc.identifier.urihttp://hdl.handle.net/10722/132648-
dc.description.abstractBackground: The current study was a phase 2 open-label study to evaluate the efficacy and tolerability of single-agent sorafenib in the treatment of advanced HCC patients in a hepatitis B-endemic Asian population. METHODS: Patients with advanced hepatocellular carcinoma (HCC) received sorafenib at a dose of 400 mg twice daily in 4-week cycles. Tumor response was assessed every 3 cycles using Response Evaluation Criteria in Solid Tumors criteria. RESULTS: Fifty-one patients were enrolled in the study and were treated with sorafenib for at least 12 weeks. The median age was 56 years (range, 28-79 years). Approximately 90% had hepatitis B virus-related HCC. Thirty-six (71%) patients had underlying Child-Pugh A cirrhosis, 13 (26%) Child-Pugh B, and 2 (3%) Child-Pugh C. Four (8%) patients achieved partial responses, and 9 (18%) patients had stable disease for at least 12 weeks. The median overall survival was 5 months (range, 4-17 months). Patients without extrahepatic spread, particularly without lung metastasis (P<.01), are more likely to benefit from sorafenib treatment. The most common toxicities were diarrhea (67%), malaise (55%), and hand-foot-skin reaction (54%). The majority of patients had transient liver function derangement. Patients with and without underlying portal vein thrombosis had similar therapeutic benefits and likewise shared a similar treatment-related toxicity profile with sorafenib treatment. CONCLUSIONS: Single-agent sorafenib demonstrates good efficacy and acceptable tolerability in treating an advanced HCC patient population in a hepatitis B-endemic area. The presence of lung metastasis predicts poor response to sorafenib in advanced HCC patients. © 2009 American Cancer Society.en_HK
dc.languageengen_US
dc.publisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www3.interscience.wiley.com/cgi-bin/jhome/28741en_HK
dc.relation.ispartofCanceren_HK
dc.subjectAdvanced hepatocellular carcinomaen_HK
dc.subjectAsianen_HK
dc.subjectLung metastasisen_HK
dc.subjectSorafeniben_HK
dc.titlePhase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian populationen_HK
dc.typeArticleen_HK
dc.identifier.emailYau, T: tyaucc@hku.hken_HK
dc.identifier.emailFan, ST: stfan@hku.hken_HK
dc.identifier.emailPoon, RT: poontp@hkucc.hku.hken_HK
dc.identifier.authorityYau, T=rp01466en_HK
dc.identifier.authorityFan, ST=rp00355en_HK
dc.identifier.authorityPoon, RT=rp00446en_HK
dc.description.naturelink_to_OA_fulltexten_US
dc.identifier.doi10.1002/cncr.24029en_HK
dc.identifier.pmid19107763-
dc.identifier.scopuseid_2-s2.0-59449089100en_HK
dc.identifier.hkuros154347-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-59449089100&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume115en_HK
dc.identifier.issue2en_HK
dc.identifier.spage428en_HK
dc.identifier.epage436en_HK
dc.identifier.eissn1097-0142-
dc.identifier.isiWOS:000262941900023-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridYau, T=23391533100en_HK
dc.identifier.scopusauthoridChan, P=7403497715en_HK
dc.identifier.scopusauthoridNg, KK=7403179075en_HK
dc.identifier.scopusauthoridChok, SH=26026200600en_HK
dc.identifier.scopusauthoridCheung, TT=7103334165en_HK
dc.identifier.scopusauthoridFan, ST=7402678224en_HK
dc.identifier.scopusauthoridPoon, RT=7103097223en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats